Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME9S8M)

• Drug Name: 2'-Monophosphoadenosine 5'-Diphosphoribose Drug Info
• Synonyms: 53-59-8; Cozymase II; Codehydrogenase II; TPN (nucleotide); Codehydrase II; Nadide phosphate; NAD phosphate; EINECS 200-178-1; BRN 3885115; nicotinamide adenine dinucleotide phosphate; CHEBI:44409; beta-NADP; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt; beta-TPN; TPN-ox; nadp nicotinamide-adenine-dinucleotide phosphate; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen p

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 46936685
  TTD Drug ID: DME9S8M

Molecule-Related Drug Atlas

Drug(s) Targeting Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[1]
3,5-dichlorosalicylic acid	DMQ45WH	Discovery agent	N.A.	Investigative	[2]
Cyclopropyl	DMGFEPJ	Discovery agent	N.A.	Investigative	[3]
Trifluoroethanol	DMAWTUL	Discovery agent	N.A.	Investigative	[4]
Cyclobutyl	DM35PIJ	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Nitric-oxide synthase brain (NOS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[5]
NXN-462	DMWVBS2	Headache	8A80-8A84	Phase 2	[6]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[7]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[1]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[8]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[1]
6-isobutyl-4-methylpyridin-2-amine	DM2XB68	Discovery agent	N.A.	Investigative	[9]
7-Methyl-[1,4]thiazepan-(5E)-ylideneamine	DMUCJA6	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Aldose reductase (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[11]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[12]
Fidarestat	DMZL1I8	Diabetic complication	5A2Y	Phase 3	[13]
Ranirestat	DMD5QRS	Diabetic neuropathy	8C0Z	Phase 3	[14]
CONTIGOSIDE B	DMX9V8K	Thrombosis	DB61-GB90	Phase 2/3	[15]
BNV-222	DMYFQJL	Diabetic neuropathy	8C0Z	Phase 2/3	[14]
BNV-222	DMYFQJL	Diabetic neuropathy	8C0Z	Phase 2/3	[16]
LIDORESTAT	DMA0RI9	Diabetic complication	5A2Y	Phase 2	[17]
QR-333	DMKVIWM	Diabetic neuropathy	8C0Z	Phase 2	[18]
ADMVA	DM819CO	Diabetic complication	5A2Y	Phase 2	[14]

Drug(s) Targeting Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[19]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[1]
APIGENIN	DMI3491	Discovery agent	N.A.	Investigative	[19]
KAEMPFEROL	DMHEMUB	Discovery agent	N.A.	Investigative	[19]
4-ANDROSTENE-3-17-DIONE	DMSE8NU	Discovery agent	N.A.	Investigative	[1]
6-(3-Hydroxy-phenyl)-naphthalen-2-ol	DMH8WA2	Discovery agent	N.A.	Investigative	[20]
7-(3-Hydroxy-phenyl)-naphthalen-2-ol	DM2I91C	Discovery agent	N.A.	Investigative	[21]
NSC-94258	DM6VY3P	Discovery agent	N.A.	Investigative	[19]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol	DM7ERYJ	Discovery agent	N.A.	Investigative	[22]
6-(4-Hydroxy-phenyl)-naphthalen-1-ol	DM2V9XI	Discovery agent	N.A.	Investigative	[21]

Drug(s) Targeting HMG-CoA reductase (HMGCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[23]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[24]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[25]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[26]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[27]
Fluvastatin	DM4MDJY	Arteriosclerosis	BD40	Approved	[24]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[28]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[24]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[29]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[28]

Drug(s) Targeting Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cacodylate Ion	DMK4XLD	Discovery agent	N.A.	Investigative	[1]
S-sulpho-L-cysteine	DMDIYWV	Discovery agent	N.A.	Investigative	[30]
Aspartate Semialdehyde	DMGB90V	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Dihydrodiol dehydrogenase type I (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[31]
ASP-9521	DM8V0UL	Prostate cancer	2C82.0	Phase 1/2	[32]
N-(benzimidazole/indole) benzoic acid derivative 2	DMOPUFM	N. A.	N. A.	Patented	[33]
N-(phenylamino)-benzoate derivative 1	DMNIWVG	N. A.	N. A.	Patented	[33]
Indomethacin analog 3	DM53JXE	N. A.	N. A.	Patented	[33]
Indomethacin analog 2	DMKFPJ7	N. A.	N. A.	Patented	[33]
Beta-naphthylacetic acids derivative 1	DM5KTDY	N. A.	N. A.	Patented	[33]
Indomethacin analog 1	DM3E5V6	N. A.	N. A.	Patented	[33]
N-(naphthylamino)-benzoate derivative 1	DM310ES	N. A.	N. A.	Patented	[33]
N-(benzimidazolylcarbonyl)-piperidine derivative 1	DM541QW	N. A.	N. A.	Patented	[33]

Drug(s) Targeting Glucose-6-phosphate dehydrogenase (G6PD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[34]
EPIANDROSTERONE	DM08XIN	N. A.	N. A.	Phase 3	[35]
CBF-BS2	DM2FAH0	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[36]
Hydroxyacetic Acid	DMQFBH6	Discovery agent	N.A.	Investigative	[1]
Metazamide	DMQBGH9	Discovery agent	N.A.	Investigative	[34]

Drug(s) Targeting Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GLYCYRRHIZIN	DM8M2N3	Influenza virus infection	1E30-1E32	Phase 3	[37]
BVT.2733	DM6RUKX	Lupus	4A40	Phase 3	[38]
INCB13739	DMLQ3PO	Type-2 diabetes	5A11	Phase 2a	[39]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[40]
JTT-654	DM50M2R	Type-2 diabetes	5A11	Phase 2	[41]
RG-4929	DMT4QRD	Metabolic disorder	5C50-5D2Z	Phase 2	[41]
BMS-770767	DMTVGY7	Hypercholesterolaemia	5C80.0	Phase 2	[41]
UE-2343	DMIERPK	Alzheimer disease	8A20	Phase 2	[5]
AZD-4017	DML9M5S	Ocular hypertension	9C61.01	Phase 2	[41]
Xanamem	DM580GT	Alzheimer disease	8A20	Phase 1/2	[42]

Drug(s) Targeting Polypeptide deformylase (PDF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[43]
Meprobamate	DMHM93Y	Anxiety		Approved	[44]
Pralatrexate	DMAO80I	Breast cancer	2C60-2C65	Approved	[45]
Ustekinumab	DMHTYK3	Plaque psoriasis	EA90.0	Approved	[46]
Trimetrexate	DMDEA85	Toxoplasmosis	1F57	Approved	[47]
MCB-3837	DM0R4Z5	Malaria	1F40-1F45	Approved	[44]
Chlorproguanil	DM1IFGT	Malaria	1F40-1F45	Approved	[44]
LY333531	DMGMC8H	Solid tumour/cancer	2A00-2F9Z	Phase 2	[48]
Metoprine	DM5GQD7	Advanced cancer	2A00-2F9Z	Phase 2	[49]
Aminopterin	DMQ9RBV	leukaemia	2A60-2B33	Withdrawn from market	[50]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aldose reductase (AKR1B1)	TTFBNVI	ALDR_HUMAN	Inhibitor	[1]
Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2)	TTQWGU9	DHAS2_VIBCH	Inhibitor	[1]
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	TTN7BL9	DHI1_HUMAN	Inhibitor	[1]
Dihydrodiol dehydrogenase type I (AKR1C3)	TT5ZWB6	AK1C3_HUMAN	Inhibitor	[1]
Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)	TTJS7O4	ADH2_ENTHI	Inhibitor	[1]
Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)	TTIWB6L	DHB1_HUMAN	Inhibitor	[1]
Glucose-6-phosphate dehydrogenase (G6PD)	TTKN8W0	G6PD_HUMAN	Inhibitor	[1]
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[1]
Nitric-oxide synthase brain (NOS1)	TTZUFI5	NOS1_HUMAN	Inhibitor	[1]
Polypeptide deformylase (PDF)	TT9SL3Q	DEFM_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Bioorg Med Chem. 2009 Feb 1;17(3):1244-50.
• [3] Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) as a target for anti-amoebic agents. J Antimicrob Chemother. 2004 Jul;54(1):56-9.
• [4] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
• [7] Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
• [8] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [9] Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
• [10] Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
• [11] Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
• [12] Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
• [13] Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
• [15] Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
• [16] ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
• [17] Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
• [18] A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
• [19] Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99.
• [20] Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
• [21] Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
• [22] New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
• [23] A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
• [24] Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
• [25] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [26] Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
• [27] New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
• [28] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [29] Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
• [30] Petrosamine B, an inhibitor of the Helicobacter pylori enzyme aspartyl semialdehyde dehydrogenase from the Australian sponge Oceanapia sp. J Nat Prod. 2005 May;68(5):804-6.
• [31] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [32] Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004.
• [33] Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
• [34] Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5.
• [35] Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. Bioorg Med Chem. 2009 Mar 15;17(6):2483-9.
• [36] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007279)
• [37] Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
• [38] Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.
• [39] Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
• [40] 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
• [41] New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
• [42] Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem?). Br J Pharmacol. 2017 Mar;174(5):396-408.
• [43] Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
• [44] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [45] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [46] Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
• [47] Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
• [48] Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
• [49] Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
• [50] Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.